Human exposomic determinants of immune mediated diseases

In HEDIMED 22 partners from 12 different countries will identify exposomic determinants, which are driving the rapid increase of immune-mediated diseases (IMDs) such as type 1 diabetes, celiac disease, allergies and asthma. The project is based on data and samples from large clinical cohorts and trials from countries with either high or low IMD incidence. Exposomic disease determinants and the underlying biological pathways will be identified using advanced omics, multiplex and data-mining technologies.

Prof Heikki Hyƶty
Tampere University Foundation, Finland
  • Tampere University Foundation, Finland (Project Coordinator)
  • Baylor College of Medicine, US
  • Charles University, CZ
  • Czech University of Life Sciences Prague, CZ
  • Copenhagen Prospective Studies on Asthma in Childhood, DK
  • Empirica MBH, DE
  • Finnish National Institute for Health and Welfare (THL), FI
  • Gnomon Informatics SA, EL
  • Graz University of Technology, AT
  • Norwegian Institute of Public Health, NO
  • Satellio Oy, FI
  • Swiss Center for Electronics and Microtechnology (CSEM SA), CH
  • Tartu University Clinic, EE
  • University of Helsinki, FI
  • University of Lund, SE
  • University of Oulu, FI
  • University of Siena, IT
  • University of Tartu, EE
  • University of Turku, FI
  • VTT Technical Research Centre, FI
January 29, 2020